Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of ...
Read More
Read More
[Job Opening] Associate, Business Operations – San Diego office
Job description Responsibilities: Provide administrative support to include arranging travel plans and meetings; interact and liaise with members of the functional team, management and external clientsPerform office duties that include ...
Read More
Read More
Yuhan Corporation – Introduction Video
Learn more about our parent company “Yuhan Corporation by watching this video ...
Read More
Read More
Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million
Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of ...
Read More
Read More
[Job Opening] Business Development Manager – San Diego office
Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, ...
Read More
Read More
Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody
Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for ...
Read More
Read More
Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation
Yuhan Corporation has in-licensed GI Innovation's allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation ...
Read More
Read More
Yuhan Corporation to recoup KRW 200 billion investment in five years
Yuhan Corporation's global R&D and open innovation strategy - in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the ...
Read More
Read More
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them ...
Read More
Read More
Yuhan to invest 14% of its sales in R&D this year for “Lazertinib’s Phase-3 trial & Global Open Innovation
In 2020, Yuhan Corporation is going to invest the largest amount in history for its R&D program to speed up the development of Lazertinib (YH25448) – the first-line treatment for ...
Read More
Read More